Poster Abstracts • OFID 2018:5 (Suppl 1) • S191 a 21.9% decrease in incident C. difficile cases (P < 0.001), while a 30% decrease in PPI use corresponded with a 9.1% reduction (P < 0.001) in incident cases. There was no evidence of a synergistic effect between the two interventions (P = 0.60). PPI stewardship also decreased length of stay, resulting in a 7% increase in admissions in the simulated ICUs (P < 0.001).
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Impact of Doxycycline in Place of Azithromycin for Community-Acquired Pneumonia on Clostridium difficile Infections
Jamie John, PharmD, Thuy Le, PharmD, BCPS and Nicole Harrington, PharmD, BCPS; Christiana Care Health System, Newark, Delaware Session: 59. Healthcare Epidemiology: Updates in C. difficile Thursday, October 4, 2018: 12:30 PM Background. As antimicrobial exposure represents a major risk factor in the development of Clostridium difficile infection (CDI), optimization of antimicrobial selection is critical. While a number of antibiotics have been associated with increased risk of CDI, doxycycline may be considered protective. The combination of ceftriaxone and doxycycline (CTX-D) is supported by the Infectious Diseases Society of America (IDSA) for the management of community acquired pneumonia (CAP). The primary objective of this study was to evaluate if CTX-D is associated with a reduced incidence of CDI compared with ceftriaxone and azithromycin (CTX-A) among nonintensive care unit (ICU) patients with CAP at Christiana Care Health System. Methods. A retrospective cohort study was conducted to evaluate patients who received CTX-D or CTX-A admitted to Christiana Care between June 1, 2015 and December 31, 2017. Non-ICU patients, aged 18 years or older, receiving at least one dose of CTX-D or CTX-A were included. The primary outcome of our study was the incidence of CDI within 30 days from initial dose of CTX-D or CTX-A. The secondary outcome was the time to onset of CDI from initial dose of CTX-D or CTX-A.
Results. One thousand sixty-four unique patients were included in this study. Overall, 778 patients received CTX-D and 286 received CTX-A. Among patients who received CTX-D, 2 patients developed CDI, compared with five patients who received CTX-A (relative risk, 0.15; 95% confidence interval, 0.03-0.75; P = 0.02). The mean time to onset of CDI from initiation of CTX-D was 22 days compared with 9.2 days from initiation of CTX-A.
Conclusion. In this cohort of non-ICU patients with CAP, CTX-D was associated with a reduced incidence of CDI. Further studies are necessary to confirm these preliminary findings to optimize clinical practice, while minimizing potential adverse outcomes associated with antimicrobial use.
Disclosures.All authors: No reported disclosures. Background. Vaccines against Clostridium difficile infection (CDI) are in development, with potential to directly protect those vaccinated and to mitigate transmission by reducing environmental contamination caused by prevented symptoms. For a vaccine that may or may not alter susceptibility to acquiring colonization, its projected transmission-reduction effect may depend on the contribution of symptomatic CDI to overall transmission, which remains uncertain. Mathematical models can help project population effects of vaccine administration under assumptions consistent with existing data.
Modeling the Potential Impact of Administering Vaccines Against Clostridium difficile Infection to Individuals in Healthcare Facilities
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Methods. We designed a simulation model of CDI among patients in a network of 10 short-and long-term acute care hospitals and nursing homes. Model calibration relied on published infection and carriage data and whole genome sequencing studies that estimated the fraction of CDI attributable to transmission from other CDI patients in healthcare settings. The modeled vaccine effectiveness for reducing the rate of progression to CDI among carriers was set at 75%, achieved after completing a vaccine course. We then simulated initiation of this vaccine course to a random subset of patients at transfer or live discharge and tallied direct and indirect CDI-reduction effects per vaccinated patient over 5 years.
Results. Model calibration found that data are consistent with higher infectivity of CDI patients over other carriers by a factor of 30-85, depending on assumed rates of initial carriage importation. Vaccine simulations produced an average reduction of 36 CDI cases per 1,000 vaccinated patients, with 25 of those cases prevented among those vaccinated and 11 prevented among unvaccinated patients. These results were robust across transmission and carriage rates supported by data.
Conclusion. Our findings demonstrate potential for a vaccine against CDI to reduce transmissions in healthcare facilities, even if it does not decrease acquisition of carriage per exposure among those receiving it. The finding is robust to the remaining uncertainty around the relative prevalence and infectivity of CDI patients among all carriers. The vaccine will have maximal impact if received by individuals likely to experience future infections in settings where environmental contamination poses risk to others. Background. We previously observed a median 9.5 days length of antibiotic therapy (LOT) among patients with community-acquired pneumonia (CAP) requiring hospitalization (Clin Infect Dis. 2018; 66:1333-41) . Treatment guidelines for CAP, however, suggest LOT >7 days is rarely necessary. In this study, we evaluated the risk of Clostridium difficile infection (CDI) as a potential harm of longer LOT.
Methods. This retrospective cohort study included Medicare beneficiaries with parts A, B, and D coverage hospitalized for uncomplicated CAP in 2012-2013 for 2-10 days, home discharge, and no hospitalizations 30 days before or 3 days after index hospitalization. The main exposure was total LOT, represented by the sum of estimated inpatient and observed outpatient LOT, and defined as "longer" if >9.5 days and "shorter" if ≤9.5 days. The outcome, post-discharge CDI, was defined using ICD-9-CM diagnosis code 008.45 in inpatient, skilled nursing, or outpatient claims within 6 months after index hospitalization. CDI 12 months before or during index hospitalization was excluded. CDI risk was assessed through a multivariable logistic model stratified by outpatient antibiotic class and adjusted for confounders including comorbidities, severity via ICU status, demographics, and hospital characteristics.
Results. The cohort consisted of 99,883 patients. Median total LOT was 9.5 days (IQR: 7.4-11.4). Antibiotics filled at discharge included quinolones (40%), none (20%), multiple (14%), cephalosporins (10%), macrolides (7%), and β-lactam/β-lactamase inhibitor combinations (5%). CDI risk was 1.2%. Overall adjusted risk among those with longer LOT was 1.2 (95% CI: 1.1-1.4) times that of those with shorter LOT. Increased risk was observed among those prescribed quinolones at discharge, for whom adjusted CDI risk for longer LOT was 1.4 (95% CI: 1.2-1.7) times the risk of those with shorter LOT. We observed no difference in risk between longer and shorter LOTs for other antibiotic categories.
Conclusion. These findings suggest that decreased LOT, which can be achieved with better adherence to current treatment guidelines, could reduce risk of subsequent CDI among patients hospitalized with CAP, particularly among those treated with fluoroquinolones at discharge.
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